Oramed Pharmaceutical Inc. TechnologyOramed is a contemporary pharmaceutical company primarily focused on the development of new, cutting-edge antidiabetic drugs that did not exist before. Like other pharmaceutical companies, technology is a key factor in the success of these companies. In an exclusive interview on www.wallst.net with Nadav Kidron, CEO of Oramed, he described Oramed Pharmaceuticals Inc. as "an Israeli company focused on developing oral delivery solutions based on proprietary technology" (PR Newswire Association LLC, 2007). Kidron's comment demonstrates the value of the technology to Oramed, which prompted the company to patent its technology and product. Lately, Oramed has focused on developing a new diabetes drug called ORMD0801. This product, in capsule form, can be consumed orally. ORMD0801, in turn, plays a role in eliminating the need for insulin administration through self-injection and constant painful testing of insulin blood levels. To accomplish this function, Oramed will need sophisticated technology and certainly high-tech equipment. Therefore, Oramed must continually obtain “licensing and other means of obtaining additional technologies to complement and/or expand its product portfolio” (The New York Times, 2012). Oramed's emerging delivery ORMD0801 is a technology in its own right. It improves the body's ability to absorb peptides and proteins through the intestinal wall without changing the active ingredients of the drug (Oramed, 2009). This was possible through the introduction of an alternative “drug delivery system” (Oramed Pharmaceuticals Inc., 2010). This distribution system will successfully deliver the drug to...... middle of paper ......012/03/20/idUS125396+20-Mar-2012+BW20120320PR Newswire Association LLC. (2007). Exclusive interview with Oramed Pharmaceuticals Inc. CEO Nadav Kidron on www.Wallst.Net. PR Newswire. ProQuest Kiosk. http://proquest.umi.com/pqdlink?vinst=PROD&fmt=3&startpage=-1&vname=PQD&RQT=309&did=1256371181&scaling=FULL&vtype=PQD&rqt=309&TS=1333335886&clientId=20655PR Newswire Association LLC. (2009). Frost and Sullivan honor Oramed Pharmaceuticals with the 2009 European Oral Drug Delivery Technology Innovation Award. PR Newswire. ^ The New York Times. (2012). Business day. Retrieved from NY Times.com: http://topics.nytimes.com/top/news/business/companies/oramed-pharmaceuticals-inc/index.html